Recruitment is one the most important parts of a clinical trial, but when literature is reviewed it seems that not reaching initial recruitment targets within initial timelines is more the rule than the exception. This indicates that current recruitment strategies are shortcoming and need to be reviewed.
This Applied Clinical Trials article describes an online, cross-sectional survey in Belgium that was conducted to systematically assess the opinions of clinical research professionals from different stakeholders about using social media as a targeting recruitment tool.
Click here for more.
Social Media and Clinical Trial Recruitment
Pharmaceutical Executive
A review of an online, cross-sectional survey in Belgium that was conducted to systematically assess the opinions of clinical research professionals from different stakeholders about using social media as a targeting recruitment tool.
Recruitment is one the most important parts of a clinical trial, but when literature is reviewed it seems that not reaching initial recruitment targets within initial timelines is more the rule than the exception. This indicates that current recruitment strategies are shortcoming and need to be reviewed.
This Applied Clinical Trials article describes an online, cross-sectional survey in Belgium that was conducted to systematically assess the opinions of clinical research professionals from different stakeholders about using social media as a targeting recruitment tool.
Click here for more.
Solving the First Mile Problem: Q&A with Mark Melton
April 26th 2024Melton, customer advocacy executive at Magnolia, discusses how new technologies can be used to ensure data is accurate.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Using AI to Create New Parkinson’s Treatments: Q&A with Matthias Alder
April 22nd 2024Alder, CEO of Gain Therapeutics, discusses how the Magellan platform was used in the creation of GT-02287.
Phase III SELECT-GCA Trial for Rinvoq Yields Promising Results in Treating Patients with Giant Cell Arteritis
April 18th 2024According to results of the study, 46% of patients with giant cell arteritis administered Rinvoq achieved sustained remission from weeks 12 to 52.
Say Hello to Flexible: Reimagining the Patient Journey
April 15th 2024Through embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.
Rare Disease Summit Recap
April 15th 2024Greater Than One’s Chief Strategy Officer, Andrew Bast, shares his takeaways from 2024 Rare Disease Summit in Philadelphia, PA.
Solving the First Mile Problem: Q&A with Mark Melton
April 26th 2024Melton, customer advocacy executive at Magnolia, discusses how new technologies can be used to ensure data is accurate.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Using AI to Create New Parkinson’s Treatments: Q&A with Matthias Alder
April 22nd 2024Alder, CEO of Gain Therapeutics, discusses how the Magellan platform was used in the creation of GT-02287.
Phase III SELECT-GCA Trial for Rinvoq Yields Promising Results in Treating Patients with Giant Cell Arteritis
April 18th 2024According to results of the study, 46% of patients with giant cell arteritis administered Rinvoq achieved sustained remission from weeks 12 to 52.
Say Hello to Flexible: Reimagining the Patient Journey
April 15th 2024Through embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.
Rare Disease Summit Recap
April 15th 2024Greater Than One’s Chief Strategy Officer, Andrew Bast, shares his takeaways from 2024 Rare Disease Summit in Philadelphia, PA.